StemCell Therapy

This article is part of an op-ed series on engineering fields that will change the world byRutgers School of Engineeringfaculty.

By Umer Hassan

Real-world innovations from submarines to self-driving cars come straight from imaginary worlds of science fiction. Think Star Treks handheld tricorder, a medical diagnostic device that made its first appearance in the original TV series. This sci-fi precursor is now changing the face of personalized medicine by taking the tricorder concept to the next level.

Today, diabetics can anticipate a biosensor able to monitor their glucose levels through perspiration. A biosensor implant could detect genetic mutations as they happen, while British researchers are developing a wearable biosensor that will collect data and assess the efficacy of rehabilitation equipment and exercise.

Other biosensors will be able to quickly and inexpensively detect costly and potentially fatal medical conditions such as sepsis and AIDS. Together with Rutgers University colleagues, clinical and industry partners, my lab has been working to solve these global health challenges with new tools that focus on a highly personalized approach to medicine. Since the COVID-19 pandemic began, we are also hoping to apply this technology to fight the coronavirus.

Sepsis the bodys life-threatening response to infection is not only deadly, it is the most expensive inpatient medical condition in the United States, with patients who develop sepsis often spending days in intensive care units at a cost of $10,000 a day or more. Recognizing that sepsis is responsible for as many as 6 million largely preventable deaths a year, the World Health Organization has identified the prevention, diagnosis and management of sepsis as a pressing global health priority.

By applying electrical and computer engineering skills to identify new biomarkers and devise machine-learning algorithms, or artificial intelligence systems, we hope to dramatically improve clinicians' abilities to diagnose, predict and ultimately manage sepsis. Simply reacting to diseases is no longer enough we need to predict them in order to treat patients in a much smarter way.

To this end, we are building an inexpensive medical device that even minimally trained health care providers can use to accurately diagnosis sepsis. This automated device would cost less than $10 a test and be simple to operate not only in resource-limited settings but anywhere where a rapidly confirmed diagnosis of sepsis is needed.

In sub-Saharan Africa, where only one person in eight is even tested for HIV, many of those infected go undetected until they develop severe complications from the disease. In the near future, cheap, disposable biosensors that are as easy and convenient to use as a home pregnancy test, will detect infections with people living with HIV/AIDS in underdeveloped sub-Saharan African nations. A secondary goal is to develop sensors able to monitor a patients response to the antiretroviral therapy they receive.

The positive health and economic impact of such sensors would be felt not only in underdeveloped nations, but also in the United States by reducing the cost of a single HIV test from hundreds of dollars to as little as $10.

A smartphone-based microscope setup, working with a Galaxy S9+ attached to a 3D printed platform will display an image of white blood cells.

My lab has also made the fight against COVID-19 a priority and a natural extension of our existing work. We are seeking to develop a sensor that could measure the ability of white blood cells to kill the virus in high-risk human patients. This could lead to new therapeutic interventions and could help develop a rapid, easy-to-use widespread stratification test.

In terms of predicting health outcomes and personalizing therapeutic approaches economically, we are also collaborating with Robert Wood Johnson Medical Hospital to do just that by combining sensor data and electronic medical records data.

Advancing personalized medicine and health monitoring is also a key concern of my Rutgers School of Engineering colleague, electrical and computer engineering associate professor Mehdi Javanmard. His lab has been developing a lab on a chip with the potential to monitor everything from health to germs to pollutants.

His teams innovative biosensor could be used in hand-held devices akin to that old Star Trek tricorder or wearable devices that measure biomarkers to track your health and exposure to harmful bacteria, viruses, and pollutants.

While a single biomarker is measured in home pregnancy tests, multiple biomarkers need to be tracked simultaneously to diagnose and manage complex health conditions such as heart disease, cancer, and inflammatory diseases. The lab on a chip is designed to meet that challenge. Additionally, within the next three to five years, a lab on a chip could quickly analyze a sample of what if any harmful bacteria are on a doorknob of a bathroom; test a salad for the presence of E. coli or Salmonella bacteria; or even quickly test for the flu.

In time, a future version of the smartphone will be the true tricorder of tomorrow. Smartphone-based health sensors will ultimately transform the smartphone into an intelligent, all-in-one monitoring and diagnostic device.

Umer Hassan, an assistant professor of electrical and computer engineering at Rutgers University School of Engineering, holds a joint appointment at Rutgers Global Health Institute.

Our journalism needs your support. Please subscribe today to NJ.com.

Heres how to submit an op-ed or Letter to the Editor. Bookmark NJ.com/Opinion. Follow us on Twitter @NJ_Opinion and on Facebook at NJ.com Opinion. Get the latest news updates right in your inbox. Subscribe to NJ.coms newsletters.

See original here:
Star Trek-inspired personalized medicine is on the horizon | Opinion - NJ.com

Ibex Medical Analytics, a company in artificial intelligence (AI)-based cancer diagnostics and Institut Curie, Frances leading cancer center, today announced a research partnership aimed at improving diagnosis of breast cancer with AI.

Breast cancer is the most common malignant disease in women worldwide, with over 2 million new cases each year. As such, accurate and timely diagnosis of breast cancer is instrumental in guiding treatment decisions and improving patient survival rates. Analysis of breast tissue samples by a pathologist, typically using gross exam followed by examination under a microscope of tissue sections from biopsies or surgical specimens, remains the standard method of diagnosing and staging cancer. However, in recent years, an increase in cancer prevalence, coupled with a decline in the number of pathologists specialized in diagnosing cancer, has resulted in greater workloads and relatively long wait times for test results. Clearly, there is a growing need for automated solutions and decision support tools that can help pathologists diagnose cancer to the utmost accuracy more rapidly, while enabling comprehensive and affordable quality control.

This research partnership, the first of its kind, will include a rich dataset of breast biopsy slides, digitized using a digital pathology scanner, and analyzed for cancer detection by Ibexs Galen Breast solution. Independently, multiple pathologists from Institut Curie will diagnose the slides, followed by blinded analysis of the AI-solutions performance. Galen Breast, the first AI solution used for detection of breast cancer in pathology, was developed utilizing state-of-the-art AI and machine learning techniques, and trained on hundreds of thousands of image samples. The solution is already deployed at the pathology institute of Maccabi Healthcare Services, Israels second largest HMO, where it is used as a second read application.

The importance of breast pathology is ever increasing, as new and more personalized treatments for breast cancer become available, many of which are based on precision medicine and require more tests and diagnosis by pathologists, said Dr. Anne Vincent-Salomon, Director of Pathology at Institut Curie and the principal investigator in the study. We believe that artificial intelligence can help us meet these challenges, and we are delighted to partner with Ibex, the leader in AI for cancer diagnosis in pathology. This collaboration will enable our pathologists to experience AI firsthand and evaluate its utility for diagnosing breast cancer.

We are excited to partner with Institut Curie, a global leader in research and treatment of breast cancer, for the first-ever blinded and independent evaluation of an AI-solution for breast cancer detection, said Daphna Laifenfeld, PhD, Chief Scientific Officer at Ibex Medical Analytics. Our Galen Prostate solution has demonstrated outstanding clinical outcomes and empowers pathologists worldwide to improve diagnostic accuracy and implement 100% quality control. We are continuing to expand our platform to new tissue types, focusing this time on breast biopsies, and are thrilled to work with Dr. Vincent-Salomon and her world-leading team on this important breast cancer study.

"This collaboration illustrates Institut Curie's approach to partnership-based research, combining the expertise of clinicians with the know-how of an innovation-driven technology company, added Amaury Martin, PhD, Head of Technology Transfer and Industrial Partnerships Office at Institut Curie and Head of Carnot Curie Cancer. It illustrates our commitment to play a major role in the development of artificial intelligence approaches applied to personalized medicine.

More:
Ibex Medical Analytics and Institut Curie Partner to Improve AI-Powered Breast Cancer Detection - Technology Networks

Metabolites, the small non-polymeric molecules, which are the intermediate or final products of metabolic reactions, have emerged as powerful tools for biomedical research and precision medicine.The term metabolome, introduced in 1998, represents the whole entity of metabolites within a cell, tissue or entire organism.1Since then, metabolomics has gained impressive traction, especially due to its relevance in systems biology or the holistic approach of deciphering the complexity of biological processes. Metabolomics fits perfectly in that concept, with its strategic position downstream of genomics and transcriptomics in the omics cascade and also tightly connected and influenced by the surrounding environmental factors. Often, the metabolome provides insights where genomic profiling fails to explain a given phenotype, and for this, the field is gaining appreciation from a plethora of pathology-related areas, including cancer, diabetes and cardiac disease.2From a technical point of view, metabolite profiling relies on the principles of analytical chemistry. The main methods are mass spectrometry (ms), applied in a targeted or untargeted manner, nuclear magnetic resonance (NMR) and stable isotope labeling for matabolomic flux analysis. Each of these methods has its pros and cons and the choice depends on the study's final goals. 3, 4The diverse nature of the metabolome continually challenges researchers and creates a colorful array of opinions on which is the most comprehensive and precise approach.

"That's kind of the way targeted metabolomics is. You're looking for certain molecules, but you're only looking under the lights. And if it turns out that this is where you've lost your keys, then it works extremely well." Patti says. Nevertheless, the scientist highly appreciates the significance of targeted metabolomics: "Targeted metabolomics is extremely useful in the clinical arena and other areas of biology," but also acknowledges the importance of identifying novel metabolites and making new discoveries. "The advantage of untargeted metabolomics is the potential for discovering molecules or metabolites that are altered in a particular disease state or physiological condition that are not expected."

Patti's lab leverages on identifying new metabolites using untargeted metabolomics and he is no stranger to the obstacles this approach offers and how it differs from the targeted analysis. "When you do untargeted metabolomics, you don't know what you're looking for. The metabolic spaces are pretty ambiguous, and we can't optimize methods in the classical way that you would do in a targeted experiment," he reflects.

Newgard has a clear vision for the future and the potential of his method: "Where I see us going is always to have that strong foundation of targeted and quantitatively reproducible and rigorous profiling, but then link it to what's happening in metabolic pathways, through the ability to do metabolic flux analysis.

Although somewhat divided into their approaches and tools, metabolomics researchers are unified by their vision for a metabolomics-based approach to personalized medicine in the future, and by the common challenges they encounter and recognize. Their collective efforts will undoubtedly pave the way for deciphering the code of metabolomics.References:

1. Oliver S. Systematic functional analysis of the yeast genome. Trends Biotechnol. 1998;16(9):373-378. doi:10.1016/S0167-7799(98)01214-1.

2. Newgard CB. Metabolomics and Metabolic Diseases: Where Do We Stand? Cell Metab. 2017;25(1):43-56. doi:10.1016/j.cmet.2016.09.018.

3. Zamboni N, Saghatelian A, Patti GJ. Defining the Metabolome: Size, Flux, and Regulation. Mol Cell. 2015;58(4):699-706. doi:10.1016/j.molcel.2015.04.021.

4. McGarrah RW, Crown SB, Zhang G-F, Shah SH, Newgard CB. Cardiovascular Metabolomics. Circ Res. 2018;122(9):1238-1258. doi:10.1161/CIRCRESAHA.117.311002.

5. Kraus WE, Muoio DM, Stevens R, et al. Metabolomic Quantitative Trait Loci (mQTL) Mapping Implicates the Ubiquitin Proteasome System in Cardiovascular Disease Pathogenesis. Lusis AJ, ed. PLOS Genet. 2015;11(11):e1005553. doi:10.1371/journal.pgen.1005553.

6. Yao C-H, Wang L, Stancliffe E, et al. Dose-Response Metabolomics To Understand Biochemical Mechanisms and Off-Target Drug Effects with the TOXcms Software. Anal Chem. 2020;92(2):1856-1864. doi:10.1021/acs.analchem.9b03811.

7.Huang X, Chen Y-J, Cho K, Nikolskiy I, Crawford PA, Patti GJ. X 13 CMS: Global Tracking of Isotopic Labels in Untargeted Metabolomics. Anal Chem. 2014;86(3):1632-1639. doi:10.1021/ac403384n.8. Lu D, Mulder H, Zhao P, et al. 13C NMR isotopomer analysis reveals a connection between pyruvate cycling and glucose-stimulated insulin secretion (GSIS). Proc Natl Acad Sci. 2002;99(5):2708-2713. doi:10.1073/pnas.052005699.

9. Warburg O, Wind F, Negelein E. The Metabolism Of Tumors in the body. J Gen Physiol. 1927;8(6):519-530. doi:10.1085/jgp.8.6.519.

Follow this link:
Diverse Opinions to Common Challenges in the Field of Metabolomics - Technology Networks

Costa Rica has the conditions to move towards the adoption of a personalized health care approach, despite some pending challenges in its objective of impacting the entire population.

A research report Personalized medicine in Latin America: Universalizing the promise of innovation, prepared by the Intelligence Unit of The Economist (EIU, for its acronym in English) indicated this and also highlighted that it is the Central American country with better social, political, economic and health conditions for its application.

To contribute to greater and better local coverage, the study recommends the construction of an initial frame of reference that includes issues of governance, awareness, and attitudes; infrastructure and financial management, where patients, the medical community, and health authorities understand the possibilities and challenges of personalized medicine in aspects such as patient and doctor education, improvements in digital and laboratory infrastructure, transition to advances in medicine, among others issues.

The study had the support of Roche Latin America and in addition to Costa Rica, it included Argentina, Brazil, Chile, Colombia, Ecuador, Mexico, Peru, and Uruguay. The nine countries were categorized as level one, two, or three, based on their assessment of the basic elements necessary for the successful implementation of personalized medicine, and where they are in the process.

The report places Costa Rica, Argentina, Brazil, Colombia, and Uruguay at level one, countries that it considers ready to decide, as it has substantial elements of the reference framework, but with important gaps in terms of its evaluation.

The best-prepared

At this level, Costa Rica is the Central American country best prepared to decide whether to create a comprehensive approach encompassing its entire health system and not just separate initiatives, which allows accompanying each patient on their journey, from prevention to treatment, monitoring and identifying their needs.

Follow this link:
Costa Rica is the Only country to advance in Personalized Medicine - The Costa Rica News

LONDON--(BUSINESS WIRE)--The RNA and DNA extraction kit market is poised to grow by USD 731.27 million during 2020-2024, decelerating at a CAGR of almost 9% during the forecast period.

For a More Detailed Analysis, Get a Free Sample Report Delivered in a Minute

The report on the RNA and DNA extraction kit market provides a holistic update, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis.

The report offers an up-to-date analysis regarding the current global market scenario and the overall market environment. The market is driven by the increasing incidence of cancer.

The RNA and DNA extraction kit market analysis includes product and geography landscape. This study identifies the increasing adoption of personalized medicine as one of the prime reasons driving the RNA and DNA extraction kit market growth during the next few years.

This report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters.

The RNA and DNA extraction kit market covers the following areas:

RNA And DNA Extraction Kit Market Sizing

RNA And DNA Extraction Kit Market Forecast

RNA And DNA Extraction Kit Market Analysis

Develop Smart Strategies for Your Business: Get a Free Sample Report Now!

Companies Mentioned

Related Reports on Health Care Include:

Global DNA Sequencing Market - Global DNA sequencing market is segmented by solution (products and services) and geography (Asia, Europe, North America, and ROW). Click Here to Get an Exclusive Free Sample Report

Global Synthetic Biology Market - Global synthetic biology market is segmented by application (healthcare, industrial, food and agriculture, and others) and geography (Asia, Europe, North America, and ROW). Click Here to Get an Exclusive Free Sample Report

Key Topics Covered:

Executive Summary

Market Landscape

Market Sizing

Five Forces Analysis

Market Segmentation by Product

Customer Landscape

Geographic Landscape

Vendor Landscape

Vendor Analysis

Appendix

Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Technavios in-depth research has direct and indirect COVID-19 impacted market research reports.

Subscribe to World-Class Market Intelligence and gain instant access to 17,000+ market research reports and connect with expert analysts

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Go here to see the original:
Global RNA and DNA Extraction Kit Market Growth Will Decelerate at a CAGR of Over 9%, 2020-2024 | However, Market Registers an Incremental Growth of $...

Today marks the start of RSNA 2020, the annual meeting of the Radiological Society of North America. I participated in my first RSNA 35 years ago and I am super excitedas I am every yearto reconnect with my radiology colleaguesand friendsand learnabout the latestmedical and scientific advances in our field. Of course, RSNA will be very different this year. Instead of traveling to Chicago to attend sessions and presentations, and wander the exhibits, Ill experience it all online. While I will miss the fun, excitement, and opportunities to connect that come with being there in person, I am amazed by what a rich and comprehensive conference the organizers of RSNA 2020 have put together using the advanced digital tools that we have at hand now.

It would be an understatement to say that this has been a year in which nearly everything is very different. From the tragic loss of life and rampant sickness to the economic disruption and the impact on our professions and our childrens education, so much of what we have been through because of COVID-19 has been extremely difficult. But the resilience of the response that so many people and institutions have shown in the face of all these challenges has been remarkable. And if it is possible to say there has been some good in all this, it would have to be the unprecedented transformation of the global healthcare ecosystem as hospitals, clinicians, and researchers have embraced a new generation of advanced digital health technologies that have helped them respond to the coronavirus crisis and laid the foundation for a more effective, affordable, and equitable future for healthcare.

As we move forward and the digital transformation of healthcare continues to accelerate, I see three significant trends that will influence the future of health and wellness.

One is the rapid emergence of virtual care through digital tools such as telehealth and remote monitoring that have made it safer and more convenient for patients to connect with their doctors during the pandemic, and that is empowering individuals to take charge of their health in entirely new ways. Virtual care has the capacity to personalize, accelerate, and augment treatment and prevention, saving time and money while improving outcomes. The ability to engage patients without requiring an in-person visit to a clinic will help ensure that they receive the right level of care and enable healthcare facilities to better manage the flow of patients into clinics and emergency rooms.

The second trend is the growing clarity of the promise of AI-driven precision medicine to serve as a major catalyst for improving health outcomes. As platforms for precision medicine and real-world evidence mature, well see exciting opportunities to improve treatment and prevention as we personalize patient care and transform how we diagnose infectious disease, cancer, and autoimmune disorders.

And, finally, where healthcare organizations have long been reluctant to move data offsite due to security, trust, and privacy concerns, we have seen a historic shift to the cloud over the last nine months. Now, driven by regulatory changes, the massive increase in medical data, and the critical need to access and analyze all that data by providers, payers, public health agencies, and researchers, its clear to everyone that moving to the cloud is both essential and hugely beneficial, both to providers and to patients.

As part of Microsofts ongoing commitment to help healthcare customers and partners continue to make progress toward recovery and build more resilient and effective systems of care, in late October we announced the general availability of Microsoft Cloud for Healthcare. This powerful industry-specific solution provides integrated capabilities for automated and efficient high-value workflows, and advanced data analysis functionally for structured and unstructured data so that healthcare organizations can truly transform information into insight and insight into action.

Built on the trusted capabilities of Microsoft 365, Microsoft Azure, Microsoft Dynamics 365, and Microsoft Power Platform, Microsoft Cloud for Healthcare is designed to enhance patient engagement to make it easier for patients to interact with caregivers, empower health team collaboration to facilitate more efficient and rich real-time communication and collaboration across the care continuum, and improve clinical and operational data insights with the ability of healthcare organizations to connect data from across their systems to predict risk and help improve patient care and operational efficiencies. Our robust partner ecosystem extends the power of Microsoft Cloud for Healthcare by building and extending advanced health solutions to meet the most demanding challenges in healthcare.

All of this makes it a particularly exciting time to be a radiologist. In many ways, our field has always been at the forefront of advances in the technologies that improve the movement, management, and analysis of large amounts of health data. This shouldnt really be a surprise, given that medical imaging accounts for nearly three-quarters of all health data, and analyzing 3D medical images can require up to 50 GB of bandwidth a day.

At Microsoft, streamlining the flow of health data, including medical imaging data, has been a significant focus of our work over the past few years. With the release of the Medical Imaging Server for DICOM (Digital Imaging and Communications in Medicine) in September, we offer developers powerful tools to ingest and persist medical imaging data in the cloud. Elevating interoperability, this is the first cloud technology to bring together DICOM data standard and FHIR (Fast Healthcare Interoperability Resources) which allows for persisting medical imaging metadata alongside other clinical data and sets the stage for multiple scenarios in research and diagnosis which may be too difficult or expensive to execute today.

Now, with Project InnerEye and the open-source InnerEye Deep Learning Toolkit, were making machine learning techniques available to developers, researchers, and partners that they can use to pioneer new approaches by training their own ML models, with the aim of augmenting clinician productivity, helping to improve patient outcomes, and refining our understanding of how medical imaging can be combined with other types of data to advance personalized medicine.

Learn more about our latest medical imaging offerings at the RSNA industry hour lunch and learn on December 3, 12:30 PM 1:30 PM Central Time.

Reimagining an industry that is as complex and touches as many lives as healthcare is a massive undertaking and at Microsoft, we have the privilege of working with amazing partners who stand at the forefront of innovation and progress in medical imaging technology.

Our partners are building transformative solutions to address some of the most difficult challenges in medical imaging. The amount of data generated by medical diagnostic imaging and connected devices is growing exponentially. Healthcare stakeholders, therefore, need effective ways of handling these data at scale.

This prompted Siemens Healthineers to build a dedicated cloud environment for Healthcare: The teamplay digital health platform. Through a certified gateway, the teamplay receiver, health data from connected medical devices can be aggregated. The teamplay cloud infrastructure is based on Azure, allowing secured processing of data within or outside a hospitals network.

GE Healthcares Centricity Universal Viewer Zero Footprint (ZFP) connects advanced diagnostic tools and system-wide image management platforms across the care continuum to help healthcare organizations improve diagnostic speed and confidence. ZFP users can now open Microsoft Teams with one click and share studies with other clinicians via the secure and compliant channels.1

SOPHiA GENETICS, the company pioneering the Data-Driven Medicine movementtrusted by over 1000 healthcare institutions in 85 countriesis highlighting their radiomics capabilities through the universal SOPHiA Platform for oncology and COVID CT imaging. Radiomics transforms standard medical imaging into mineable data assets that can be analyzed and combined with genomic data for improved decision support of precision medicine. SOPHiA Radiomics Solutions offer comprehensive workflows for multiple research and disease indication needs. SOPHiA multimodal platform is deployed on Microsoft Azure Cloud.

Microsoft and Sectra are partnering on cloud-based enterprise imaging and AI. In our joint RSNA webinar, Reap the benefits of enterprise imaging in the cloud with Microsoft & Sectra on December 3, we will introduce the brand new all-Azure and hybrid Microsoft Azure Stack offering as well as a demo of how Teams integration will help radiologists to cope in the new virtual world. We will hear Judy Bartlett from our joint customer John Muir share her experiences about moving from on-prem to running the Sectra Enterprise Imaging Solution as a Service on Azure.

With the imminent release of a new version of iConnect Enterprise Archive, IBM Watson Health will start to bring to market solutions that support a containerized deployment, in addition to VMWare, on both the IBM Cloud and Azure. The containerization of this portfolio is one of IBM Watson Healths key initiatives, starting with their VNA foundation and leveraging IBMs Red Hat OpenShift technology to ensure build once and deploy anywhere to be cloud native and agnostic.

With NVIDIA Clara Imaging, developers and researchers have the ability to accelerate data annotation, build domain-specialized AI models, and deploy intelligent imaging workflows with state-of-the-art pre-trained models and reference applications. Working closely with Azure, these innovators can jumpstart their development in the cloud and also address tough medical imaging challenges faster.During the current pandemic, our partnership is heavily accelerating progress Research in drug discovery (UC, Riverside; UCB Covid Moonshot) using GPUs on Azure for quantum mechanics model as well as using AI for SARS COVID-19 risk evaluation in Italy (Hospital San Raffaele, Milan). This partnership also enables the development and deployment of smart hospital solutions, running on NVIDIA Clara Guardian and Azure.

And finally,Flywheel is a cloud-scale informatics platform for biomedical research and collaboration. What is exciting about their differentiated work is the ability to securely leverage cloud at the edge with Microsoft Azure Stack Hub and transform these image analytics with Microsoft AI enabling tools and Flywheels depth in medical imaging data management and automated workflows.

Microsoft is the only cloud that extends to the edge from Microsoft Azure Edge Zone for 5G to Microsoft Azure Sphere for security. Were removing all barriers by covering all security and data sovereignty concerns in the cloud. With over 168,000 partners around the world, the network for innovation and collaboration runs deep. We cannot wait to see how together we will build solutions that transform healthcare around the world.

For more information on Microsoft Cloud for Healthcare, AI imaging tools, or to learn more about partnership visit the Microsoft virtual booth at RSNA or connect with us at our featured demo on November 29, 2:00 PM 2:30 PM Central Time.

[1] Technology in development that represents ongoing research and development efforts. These technologies are not products and may never become products. Not for sale. Not cleared or approved by the U.S. FDA or any other global regulator for commercial availability.

Go here to see the original:
Medical imaging, AI, and the cloud: what's next? - Microsoft Industry Blogs - Microsoft

LONDON--(BUSINESS WIRE)--Technavio has been monitoring the cycling jersey market and it is poised to grow by USD 237.28 million during 2020-2024, progressing at a CAGR of over 8% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.

Click & Get Free sample report in minutes

Impact of COVID-19

The COVID-19 pandemic continues to transform the growth of various industries. However, the immediate impact of the outbreak is varied. While a few industries will register a drop in demand, numerous others will continue to remain unscathed and show promising growth opportunities. COVID-19 will have a low impact on the cycling jersey market. The market growth in 2020 is likely to increase compared to the market growth in 2019.

Frequently Asked Questions-

Related Reports on Consumer Discretionary Include:

Global Cycling Wear Market: The cycling wear market size has the potential to grow by USD 2.98 billion during 2020-2024, and the markets growth momentum will accelerate during the forecast period because of the steady increase in year-over-year growth. To get extensive research insights: Click and Get FREE Sample Report in Minutes!

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

The market is fragmented, and the degree of fragmentation will accelerate during the forecast period. ASSOS of Switzerland GmbH, adidas AG, FOX HEAD Inc., Giant Manufacturing Co. Ltd., Jaggad Pty Ltd., Pending System GmbH & Co. KG, Rapha Racing Ltd., Shimano Inc., Trek Bicycle Corp., and Troy Lee Designs Inc. are some of the major market participants. The growing need for fitness activities will offer immense growth opportunities. In a bid to help players strengthen their market foothold, this cycling jersey market forecast report provides a detailed analysis of the leading market vendors. The report also empowers industry honchos with information on the competitive landscape and insights into the different product offerings offered by various companies.

Technavio's custom research reports offer detailed insights on the impact of COVID-19 at an industry level, a regional level, and subsequent supply chain operations. This customized report will also help clients keep up with new product launches in direct & indirect COVID-19 related markets, upcoming vaccines and pipeline analysis, and significant developments in vendor operations and government regulations.

Cycling Jersey Market 2020-2024: Segmentation

Cycling Jersey Market is segmented as below:

To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR41655

Cycling Jersey Market 2020-2024: Scope

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources. The cycling jersey market report covers the following areas:

This study identifies growing demand for personalized medicine as one of the prime reasons driving the cycling jersey market growth during the next few years.

Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Technavios in-depth research has direct and indirect COVID-19 impacted market research reports.

Register for a free trial today and gain instant access to 17,000+ market research reports.

Technavio's SUBSCRIPTION platform

Cycling Jersey Market 2020-2024: Key Highlights

Table of Contents:

Executive Summary

Market Landscape

Market Sizing

Five Forces Analysis

Market Segmentation by Distribution channel

Customer Landscape

Geographic Landscape

Vendor Landscape

Vendor Analysis

Appendix

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

More:
Cycling Jersey Market to grow by USD 237.28 million during 2020-2024, ASSOS of Switzerland GmbH and adidas AG Emerge as Key Contributors to Market...

NEW YORK, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (AI) to personalized medicine and drug discovery, today announced that its virtual Special Meeting of Stockholders, scheduled for December 1, 2020, was convened and adjourned without any business being conducted due to the fact that quorum was not achieved. The Special Meeting will be reconvened December 30, 2020 at 3 p.m. CST and will be conducted via live audio webcast at http://www.virtualshareholdermeeting.com/POAI2020SM, so as to allow more opportunity for stockholders to vote on all proposals described in the Companys definitive proxy statement filed with the Securities and Exchange Commission (SEC) on November 3, 2020.

The record date for the Special Meeting remains October 28, 2020. Stockholders of record may vote at the reconvened Special Meeting, vote by proxy using the proxy card enclosed with the Companys definitive proxy statement, vote by proxy via facsimile, email or on the Internet. Whether or not stockholders of record plan to attend the reconvened Special Meeting, the Companys Board of Directors and management urge them to vote by proxy to ensure their vote is counted. Stockholders who have previously submitted their proxy or otherwise voted and who do not want to change their vote need not take any action.

A copy of the Companys proxy statement as previously filed with the SEC is available at no charge on the SEC website at http://www.sec.gov. In addition, copies of the proxy statement and other documents may be obtained free of charge by accessing the Companys website at https://investors.predictive-oncology.com/ or by contacting the Companys Corporate Secretary at (651) 389-4806 or by mail to Corporate Secretary, Predictive Oncology Inc., 2915 Commers Drive, Suite 900, Eagan, MN 55121.

YOUR PARTICIPATION IS IMPORTANT - PLEASE VOTE TODAY!

About Predictive Oncology Inc.

Predictive Oncology (NASDAQ: POAI) operates through three segments (Skyline, Helomics and Soluble Biotech), which contain four subsidiaries: Helomics, TumorGenesis, Skyline Medical and Soluble Biotech.

Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. TumorGenesis Inc. specializes in media that help cancer cells grow and retain their DNA/RNA and proteomic signatures, providing researchers with a tool to expand and study cancer cell types found in tumors of the blood and organ systems of all mammals, including humans. Skyline Medical markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. Soluble Biotech is a provider of soluble and stable formulations for proteins including vaccines, antibodies, large and small proteins and protein complexes.

Forward-Looking Statements

Certain matters discussed in this release contain forward-looking statements. These forward-looking statements reflect our current expectations and projections about future events and are subject to substantial risks, uncertainties and assumptions about our operations and the investments we make. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future revenue and financial performance, projected costs, prospects, plans and objectives of management are forward-looking statements. The words anticipate, believe, estimate, expect, intend, may, plan, would, target and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Our actual future performance may materially differ from that contemplated by the forward-looking statements as a result of a variety of factors including, among other things, factors discussed under the heading Risk Factors in our filings with the SEC. Except as expressly required by law, the Company disclaims any intent or obligation to update these forward-looking statements.

Investor Relations Contact:

Hayden IRJames Carbonara(646)-755-7412

Excerpt from:
Predictive Oncology Announces Adjournment of Special MeetingScheduled to Reconvene on December 30, 2020 - BioSpace

The Scientist's annual award recognizes exciting biomedical technologies that have the potential to generate the biggest impact on scientific research. Seven Bridges GRAF was selected by The Scientist's independent panel of expert judges for its potential to improve methods for analyzing next-generation sequencing data, helping researchers overcome the inherent flaws in the human genome linear reference sequence, and improving understandings of genetic diversity in understudied populations such as people of African, Asian, Hispanic and Middle Eastern descent.

"Seven Bridges is the first to offer this type of graph-based bioinformatics solution," said William Moss, CEO of Seven Bridges. "This recognition underscores the greater importance Seven Bridges GRAFTMbrings to the research community and its value in helping scientists develop new understandings of global population diversity. We hope that this research ultimately improves precision medicine across global populations."

The company's comprehensive graph-based bioinformatics solution is designed to greatly improve the analysis of non-European ethnicities; support large, more diverse population studies; enable research on underrepresented populations; and aid in the development of personalized references for more precise analysis. Seven Bridges GRAF enables:

"The COVID-19 pandemic birthed a shared scientific purpose and accelerated innovation in 2020," said The Scientist Editor-in-Chief Bob Grant. "The winners of this year's competition embody the spirit of togetherness and ingenuity marshaled by the research community in the face of this unprecedented challenge."

In addition to the honor from The Scientist, this year, Seven Bridges GRAF was selected as the top performer in the precisionFDA Truth Challenge for the major histocompatibility complex (MHC) region. The MHC region contains highly polymorphic genes that play a vital role in the immune system, making it difficult to accurately process NGS data in this region.

"The MHC region contains highly polymorphic genes that play a vital role in the immune system, making it difficult to accurately process NGS data in this region," said Dr. H. Serhat Tetikol, the GRAF Product Director at Seven Bridges. "From a computational perspective, the complexity of such genomic loci is only exacerbated when one takes into account the variation between different ancestries. This is where the current linear human genome reference clearly falls short, and where our GRAF technology can provide significant utility over traditional methods."

For more information about Seven Bridges GRAF, visit http://www.sevenbridges.com/graf/.

About Seven BridgesSeven Bridges enables researchers to extract meaningful insights from genomic and phenotypic data in order to advance precision medicine. The Seven Bridges Ecosystem consists of a compliant analytic platform, intelligently curated content, transformative algorithms, unprecedented access to federated data sets, and expert on-demand professional services. This holistic approach to bioinformatics is enabling researchers at the world's leading academic, biotechnology, clinical diagnostic, government, medical centers, and pharmaceutical entities to increase R&D efficiency, enhance the hypothesis resolution process, isolate critical biomarkers, and even turn a failing clinical trial around while also reducing computational workflow times and data storage costs. To learn more, visitsevenbridges.comor follow us onLinkedInandTwitter.

Contact: Eric Schubert +1 415 692 6799 [emailprotected]

SOURCE Seven Bridges

Home

Read the rest here:
Seven Bridges GRAF Named #3 on The Scientist's Top 10 Innovations List for 2020 - PRNewswire

Optimal patient stratification is critical in the era of personalized medicine. Germline polymorphisms play an important role in the treatment response of various human diseases, including bladder cancer. Intravesical BCG therapy is widely-used for bladder cancer. However, tumor recurrence and progression are very common. Stratification based on germline polymorphisms may contribute to circumvent this clinical challenge. Autophagy pathway plays an important role in the nonspecific protective effects of BCG. Patients that carry C allele of rs3759601 in autophagy gene ATG2B showed increased risk of recurrence and progression in European population. We thus sought to analyze rs3759601 and its relevance in BCG response in Asian NMIBC patients.

Functional impact of rs3759601 ATG2B (p.Gln1383Glu) was analyzed by bioinformatics programs including NCBI Conserved Domain Search, Clustal Omega, Polyphen and SIFT. NMIBC patients who received intravesical BCG at multiple hospitals in Singapore from 1995 to 2016 were included. These patients were genotyped for rs3759601 using high resolution melt analysis. The rs3759601 polymorphism was studied in correlation with the bladder cancer recurrence rate and disease progression rate in our cohort. Statistical analysis was conducted using Kaplan-Meier plots and the Chi-squared analysis.

In total, 307 individules were included in the study including 161 NMIBC patients and 146 healthy controls, predominately Chinese. The rs3759601 genotype distributions in our NMIBC patients were (GG 72.1%; GC 27.9%; CC 0%), which were distinct from the Dutch report (GG 32.8%; GC 47.4% and CC 19.8%, Buffen K et al, 2014). Consistently, the C allele frequencies of rs3759601 are 0.171 in our controls and 0.177 in East Asians from 1,000 Genome, but 0.406 in Europeans from 1,000 Genome. In silico analysis suggested rs3759601 ATG2B (p.Gln1383Glu) alteration is unlikely to be functionally deleterious. Statistical analysis revealed no significant association between ATG2B rs3759601 C allele and risk of bladder cancer recurrence (P= 0.353, GC vs. GG: hazard ratio [HR]= 1.324), or cancer progression (P= 0.454, GC vs. GG: HR=0.658).

In contrast to European NMIBC patients, ATG2B rs3759601 C allele is much less common in Asians and it not associated with BCG response in Asian NMIBC patients.

Urologic oncology. 2020 Nov 26 [Epub ahead of print]

Zhijiang Zang, Yew Koon Lim, Yiong Huak Chan, Lata Raman, Kesavan Esuvaranathan, Edmund Chiong, Ratha Mahendran

Department of Urology, National University Hospital, National University Health System, Singapore. Electronic address: ., Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Singapore., Biostatistics Unit, Yong Loo Lin School of Medicine, National University of Singapore, Singapore., Department of Urology, National University Hospital, National University Health System, Singapore; Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.

PubMed http://www.ncbi.nlm.nih.gov/pubmed/33250346

Read the original:
Polymorphism in autophagy gene ATG2B is not associated with bladder cancer recurrence after intravesical Ba... - UroToday

Hologics Jennifer Meade, division president of breast and skeletal care, discusses the focus for breast imaging in the near future and some latest technologies.

Hologic received 510(k) clearance from the U.S. Food & Drug Administration for its Genius AI Detection software this week during the Radiology Society of North America (RSNA) annual meeting. This move is one more development that is feeding growing trends in breast imaging, said Jennifer Meade, division president of breast and skeletal care for womens imaging vendor Hologic.

Meade spoke with Diagnostic Imaging not only about some of Hologics more recent product offerings, but she also discussed feedback from the radiology community and some growing trends in breast imaging. In the coming years, she said, the industry can expect to see a greater focus on improved patient outcomes, workflow efficiency, and patient experience. In addition, she said developments and investments will continue around artificial intelligence, as well as personalized medicine.

With this latest FDA clearance, the Genius AI Detection software is set to follow that path, according to company information. It is designed to optimize workflow in four specific ways by providing a case score that reflects confidence of malignancy, categorizing cases based on the number of lesions present, flagging the most concerning cases in less than a minute, and providing an estimate of how much time a radiologist can expect the image review to take.

For more RSNA coverage, click here.

Read more:
Trends in Breast Imaging Care: Improving Outcomes, Efficiency, and Experience - Diagnostic Imaging

DataIntelo, a prominent market research firm, has published a detailed report on Global Personalized Medicines Market. This market research report provides comprehensive and in-depth analysis on the market which can possibly help an enterprise to identify lucrative opportunities and assist them with fabricating creative business strategies. The market report provides information about the current market scenario regarding the global supply and demand, key market trends and opportunities in the market, and challenges and threats faced by the industry players.

The Personalized Medicines market report talks about the competitive scenario among the industry players and imparts aspiring and emerging industry players with the future market insights in a detailed manner. This market report includes crucial data and figures which are structured out in a concise yet understandable manner. The research report covers the updates on the government regulations and policies which illustrates key opportunities and challenges of the market. DataIntelo has been monitoring the market since few years and collaborated with eminent players of the industry to give better insights on the market. It has conducted vigorous research and implied robust methodology to provide accurate predictions about the market.

You can buy the complete report on @ https://dataintelo.com/checkout/?reportId=98645

Impacts of Advancements and COVID-19 on the market.

Amidst the COVID-19, few segments of the market have witnessed a disruption due to the gap in supply and demand which has impacted the growth of the Personalized Medicines market. Along with this, the latest advancements have changed the market dynamics of the market. This research report covers the wide-range analysis of the COVID-19 impact to the industry and gives out insights on the change in the market scenario due to the advancements.

Request A Free Sample Report @ https://dataintelo.com/request-sample/?reportId=98645

Market Segmentation

Some of the major companies that are covered in the report.

3G BiotechQuest DiagnosticsLaboratory Corporation of AmericaAbbottAgendia NVAsuragen IncBecton DickinsonCardioDx Inc.Foundation MedicineQiagenSiemens HealthcareAmgenBristol-Myers SquibbGE HealthcarePfizerSanofi23andMeIllumina

Note: Additional companies

Based on the type, the market is segmented into

PM DiagnosticsPM TherapeuticsPersonalized Medical CarePersonalized Nutrition & Wellness

Based on the application, the market is segregated into

Hospitals PharmaciesRetail PharmaciesDietary Care CentersOthers

Based on the geographical location, the market is segregated into

Asia Pacific: China, Japan, India, and Rest of Asia PacificEurope: Germany, the UK, France, and Rest of EuropeNorth America: The US, Mexico, and CanadaLatin America: Brazil and Rest of Latin AmericaMiddle East & Africa: GCC Countries and Rest of Middle East & Africa

DataIntelo provides yearly updates on the Personalized Medicines market that assist the clients to stay ahead in the competitive space.

Why one should buy this Personalized Medicines Report?

The market research report provides all valuable constituents of the market such as revenue growth, product pricing & analysis, growth potential, and guidelines to tackle the challenges in the market. The report covers all the crucial mergers & acquisitions, partnerships, and collaborations that created further created opportunities or in some cases, challenges for the industry players.

This report includes latest product news, advancements, and updates from the prominent player of the industry that has leveraged their position in the market. It also provides business strategies implemented by the key players and yardstick to arrive on informed business decisions. Moreover, it gives insights on the consumer behavior patterns that can help the enterprise to curate the business strategies accordingly.

DataIntelo bestows the clients with the specialized customized options related to the regional analysis, company analysis, and product analysis, among others.

Complete Table Content of the Market

Executive Summary

Assumptions and Acronyms Used

Research Methodology

Personalized Medicines Market Overview

Personalized Medicines Supply Chain Analysis

Personalized Medicines Pricing Analysis

Global Personalized Medicines Market Analysis and Forecast by Type

Global Personalized Medicines Market Analysis and Forecast by Application

Global Personalized Medicines Market Analysis and Forecast by Sales Channel

Global Personalized Medicines Market Analysis and Forecast by Region

North America Personalized Medicines Market Analysis and Forecast

Latin America Personalized Medicines Market Analysis and Forecast

Europe Personalized Medicines Market Analysis and Forecast

Asia Pacific Personalized Medicines Market Analysis and Forecast

Asia Pacific Personalized Medicines Market Size and Volume Forecast by Application

Middle East & Africa Personalized Medicines Market Analysis and Forecast

Competition Landscape

If you have any questions on this report, please reach out to us @ https://dataintelo.com/enquiry-before-buying/?reportId=98645

About the Company

DataIntelo is the largest aggregator of the market research report in the industry with more than 800 global clients. The company has extensively invested in the research analysts training and programs to keep the analyst tapped with the best industry standards and provide the clients with the&utmost experience. Our dedicated team has been collaborating with the industry experts to give out the precise data and figures related to the industry. It conducts primary research, secondary research, and consumer surveys to provide an in-depth analysis of the market. The market research firm has worked in several business verticals and has been successful to earn high credentials over the time.

Contact Info:

Name: Alex Mathews

Address: 500 East E Street, Ontario,

CA 91764, United States.

Phone No: USA: +1 909 545 6473

Email:[emailprotected]

Website:https://dataintelo.com

Continued here:
Personalized Medicines Market 2020 |Global Industry Analysis By Trends, Size, Share, Company Overview, Growth And Forecast By 2026| Latest Research...

CHICAGO, Nov. 26, 2020 /PRNewswire/ -- BASE10 Genetics and DNA Link today announced their collaboration on a research project to evaluate the usability of DNA Link's AccuFind COVID-19 IgG antibody test in a healthcare setting.

Study will expand access to antibody testing outside of laboratory settings

Although Covid-19 deaths and new confirmed cases continue to rise across nursing homes in the US, many of those infected do recover. This has led to growing interest in the relationship between antibodies and their protective value whether generated by previous Covid-19 exposure or by a vaccine, once available.

At present, most antibody tests on the market require samples to be sent to a lab for analysis. The extra cost and time associated has constrained population wide studies of SARS-CoV-2 antibodies.

"An antibody test that can be done at the point of care without the need for a lab can more quickly provide information clinicians and administrators need to make decisions for their nursing home patients and staff," says Dr. Michael Fang, BASE10 CEO.

"This research is an important milestone in our efforts to expand access to antibody testing," says Elizabeth Freund, VP of Innovation at BASE10. "DNA Link's AccuFind performs very well in laboratory settings. The next logical step is to test its performance when used by healthcare professionals outside the lab. Many factors have the potential to affect test performance in lesser controlled settings so it's an ambitious goal to be sure. However, if FDA believes the data demonstrates its safety and effectiveness under these conditions, we'll be one step closer to FDA emergency use authorization for point of care use."

The study is set to launch in December.

About BASE10 Genetics, Inc.BASE10 is a precision medicine company based in Chicago. BASE10's proprietary platform identifies precision diagnostics technologies with high potential for improving health outcomes, and creates turnkey, disease management programs that can be deployed at scale for insurance payors.

For more information about BASE10 Genetics and its solutions, contact media@base10genetics.com.

About DNA Link, Inc.DNA Link, Inc. is a leading genomic service corporation based in Korea with a focus on personalized medicine and new drug development. The company combines biotechnology with information & communications technology to support total analysis of genomic and clinical information to accelerate research and development in the field of bio-industry and genomic analysis industry.

For more information about DNA Link and its solutions, contact ikjun.choi@dnalink.com

View original content:http://www.prnewswire.com/news-releases/base10-and-dna-link-partners-on-research-to-support-authorization-of-antibody-test-at-the-point-of-care-301181072.html

SOURCE BASE10 Genetics, Inc.

Read the rest here:
BASE10 and DNA Link Partners on Research to Support Authorization of Antibody Test at the Point of Care - BioSpace

The Personalized Medicines Market grew in 2019, as compared to 2018, according to our report, Personalized Medicines Market is likely to have subdued growth in 2020 due to weak demand on account of reduced industry spending post Covid-19 outbreak. Further, Personalized Medicines Market will begin picking up momentum gradually from 2021 onwards and grow at a healthy CAGR between 2021-2025

Deep analysis about market status (2016-2019), competition pattern, advantages and disadvantages of products, industry development trends (2019-2025), regional industrial layout characteristics and macroeconomic policies, industrial policy has also been included. From raw materials to downstream buyers of this industry have been analysed scientifically. This report will help you to establish comprehensive overview of the Personalized Medicines Market

Get a Sample Copy of the Report at: https://i2iresearch.com/report/global-personalized-medicines-market-2020-market-size-share-growth-trends-forecast-2025/

The Personalized Medicines Market is analysed based on product types, major applications and key players

Key product type:PM DiagnosticsPM TherapeuticsPersonalized Medical CarePersonalized Nutrition & Wellness

Key applications:Hospitals PharmaciesRetail PharmaciesDietary Care CentersOthers

Key players or companies covered are:3G BiotechQuest DiagnosticsLaboratory Corporation of AmericaAbbottAgendia NVAsuragen IncBecton DickinsonCardioDx Inc.Foundation MedicineQiagenSiemens HealthcareAmgenBristol-Myers SquibbGE HealthcarePfizerSanofi23andMeIllumina

The report provides analysis & data at a regional level (North America, Europe, Asia Pacific, Middle East & Africa , Rest of the world) & Country level (13 key countries The U.S, Canada, Germany, France, UK, Italy, China, Japan, India, Middle East, Africa, South America)

Inquire or share your questions, if any: https://i2iresearch.com/report/global-personalized-medicines-market-2020-market-size-share-growth-trends-forecast-2025/

Key questions answered in the report:1. What is the current size of the Personalized Medicines Market, at a global, regional & country level?2. How is the market segmented, who are the key end user segments?3. What are the key drivers, challenges & trends that is likely to impact businesses in the Personalized Medicines Market?4. What is the likely market forecast & how will be Personalized Medicines Market impacted?5. What is the competitive landscape, who are the key players?6. What are some of the recent M&A, PE / VC deals that have happened in the Personalized Medicines Market?

The report also analysis the impact of COVID 19 based on a scenario-based modelling. This provides a clear view of how has COVID impacted the growth cycle & when is the likely recovery of the industry is expected to pre-covid levels.

Contact us:i2iResearch info to intelligenceLocational Office: *India, *United States, *GermanyEmail: [emailprotected]Toll-free: +1-800-419-8865 | Phone: +91 98801 53667

Continued here:
Personalized Medicines Market Segmentation by Application, Market landscape, Market size and forecast by 2026 - The Market Feed

Latest added DNA Sequencing Market research study by MarketDigits offers detailed product outlook and elaborates market review till 2026. The market Study is segmented by key regions that is accelerating the marketization. At present, the market is sharping its presence and some of the key players in the study are GE Healthcare Life Sciences, Johnson & Johnson, Commonwealth Biotechnologies, ZS Genetics, Agilent Technologies, Siemens AG. The study is a perfect mix of qualitative and quantitative Market data collected and validated majorly through primary data and secondary sources.

This report studies the DNA Sequencing Market size, industry status and forecast, competition landscape and growth opportunity. This research report categorizes the DNA Sequencing Market by companies, region, type and end-use industry.

Request for Free Sample Copy of This Report (with COVID-19 Impact ) @ https://marketdigits.com/dna-sequencing-market/sample

Scroll down 100s of data Tables, charts and graphs spread through Pages and in-depth Table of Content on DNA Sequencing Market By Product Type (Instruments, Consumables, and Others), Platform (Sanger, Next Generation Sequencing, qPCR, and Others), Application (Diagnostics, Personalized Medicine, and Others), End User (Hospitals & Healthcare Organizations, Academics & Research Institutions, Pharmaceutical & Biotechnology Companies, and Others) and Geography Global Forecast To 2026. Early buyers will get 10% customization on study.

To Avail deep insights of DNA Sequencing Market Size, competition landscape is provided i.e. Revenue Analysis (M $US) by Company (2018-2020), Segment Revenue Market Share (%) by Players (2018-2020) and further a qualitative analysis is made towards market concentration rate, product/service differences, new entrants and the technological trends in future.

Unlock new opportunities in DNA Sequencing Market; the latest release from MarketDigits highlights the key market trends significant to the growth prospects, Let us know if any specific players or list of players needs to consider to gain better insights.

Grab Complete Details with TOC For Free @ https://marketdigits.com/dna-sequencing-market/toc

Global DNA Sequencing Market: Synopsis

The global DNA sequencing market is projected to achieve an impressive growth rate on the back of its extensive usage in a number of applications and ease of adoption with the emergence of innovative technologies in the field. A DNA sequencing Android app named GelApp 2.0 has been recently introduced with a 56.0% greater band detection accuracy for proteins and 36.0% for DNA than its original version. The interesting, rather most innovative, part of the apps development procedure was the implementation of Monte Carlo Tree Search, a gaming algorithm, for cutting-edge image processing.

With a healthy CAGR of 17.5%, the worldwide DNA sequencing market is foretold to expand substantially from an estimated US$6.6 billion in 2016.

The segmentation followed in this global DNA sequencing report touches four important parameters, including technology. With the help of such critical market segmentation, the analysts have provided a comprehensive study of the global market and significant segments that are envisaged to make a statement in the near future. An illustrative portion on SWOT analysis of the chief segments of the DNA sequencing sector, including characteristic graphics, helps to easily analyze the future outlook of the market.

The report on the international DNA sequencing market takes into account the industry growth drivers, challenges for market players, and current trends impacting the industry. With such conclusive data and accurate statistics, report buyers can devise result-oriented strategies to secure a competitive place in the global market. An in-depth evaluation of the key factors of the market illustrated in the report is a crucial stepping stone to make important business decisions.

Global DNA Sequencing Market : Trends and Opportunities

New market players are envisioned to get attracted to the global DNA sequencing market as technological innovations keep taking precedence. Besides this, established players can expect to leverage new opportunities in the market with sophisticated technologies such as chain terminator DNA sequencing and next generation DNA sequencing. Vendors can also find lucrative opportunities in the clinical field as DNA sequencing is highly demanded in numerous clinical applications. Next generation DNA sequencing, particularly, is receiving high attention with the providence of novel platforms from the ongoing quantum leaps in microfluidics, bioinformatics, nanotechnology, and imaging. Such breakthroughs are also predicted to revolutionize a number of life science fields, thus providing an easy path of growth for the global market.

The services segment of the international DNA sequencing market had secured a colossal share in 2016 while instruments and consumables was one of the most rapidly growing segments in the same year.

Global DNA Sequencing Market: Geography

Considering the most critical geographical regions as a base, the analysts have offered an all-encompassing interpretation of the global DNA sequencing market. North America, Europe, Asia Pacific, and Rest of the World are the major geographies studied in the report. North America could hold a momentous share in the global market while Asia Pacific is anticipated to take advantage of the demand for personalized medicine and higher awareness.

Global DNA Sequencing Market: Company Profiling

Among other prominent players in the global DNA sequencing market, Microchip Biotechnologies, Beckman Coulter (Fullerton, CA), Abbott Laboratories, GE Healthcare Life Sciences, Johnson & Johnson, Commonwealth Biotechnologies, ZS Genetics, Agilent Technologies, Siemens AG, Pacific Biosciences, Myriad Genetics, Bayer Corporation, Integrated DNA Technologies, 454 Life Sciences, Hamilton Thorne Biosciences, and LI-COR Biosciences (Lincoln, NE) are expected to make their presence known.

Market segmentation based on type:

Market segmentation based on technology:

This study by MarketDigits is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers or customers journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.

Below is a snapshot of these quadrants.

1. Customer Experience Map

The study offers an in-depth assessment of various customers journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.

2. Actionable Results

The findings presented in this study by MarketDigits are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.

3. Strategic Frameworks

The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at MarketDigits helps you break down the complex scenario and bring resiliency in uncertain times.

The DNA Sequencing market research report makes an organization armed with data and information generated by sound research methods. This market analysis helps to get up to date about various segments that are relied upon to observe the rapid business development amid the estimate forecast frame. This market research report offers an in-depth overview of product specification, technology, product type and production analysis considering major factors such as revenue, cost & gross margin. DNA Sequencing market report plays very essential role when it is about achieving an incredible growth in the business.

The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:

1. What can be the best investment choices for venturing into new product and service lines?

2. What value propositions should businesses aim at while making new research and development funding?

3. Which regulations will be most helpful for stakeholders to boost their supply chain network?

4. Which regions might see the demand maturing in certain segments in near future?

5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?

6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?

7. Which government regulations might challenge the status of key regional markets?

8. How will the emerging political and economic scenario affect opportunities in key growth areas?

9. What are some of the value-grab opportunities in various segments?

10. What will be the barrier to entry for new players in the market?

DNA Sequencing Market Reports Table of Contents

1.1. Market Definition and Scope

1.2. Market Segmentation

1.3. Key Research Objectives

1.4. Research Highlights

4.1. Introduction

4.2. Overview

4.3. Market Dynamics

4.4. Porters Five Force Analysis

5.1. Technological Advancements

5.2. Pricing Analysis

5.3. Recent Developments

Any Questions? Inquire Here Before Buying @ https://marketdigits.com/dna-sequencing-market/analyst

About Market Digits :

MarketDigits is one of the leading business research and consulting companies that helps clients to tap new and emerging opportunities and revenue areas, thereby assisting them in operational and strategic decision-making. We at MarketDigits believe that market is a small place and an interface between the supplier and the consumer, thus our focus remains mainly on business research that includes the entire value chain and not only the markets.

We offer services that are most relevant and beneficial to the users, which help businesses to sustain in this competitive market. Our detailed and in-depth analysis of the markets catering to strategic, tactical, and operational data analysis & reporting needs of various industries utilize advanced technology so that our clients get better insights into the markets and identify lucrative opportunities and areas of incremental revenues.

Contact Us :

Market Digits

Phone : +91-9822485644

Email : sales@marketdigits.com

Read the original post:
DNA Sequencing Market : Overview Report by 2020, Covid-19 Analysis, Future Plans and Industry Growth with High CAGR by Forecast 2026 - The Courier

Janssen is tapping little-known and privately held Hemera Biosciences for a new gene therapy aimed at reversing a severe disease.

The deal, financials of which are not being shared, is for the investigational phase 1 gene therapy HMR59, which is given as a one-and-done shot into the eye with the aim of helping preserve vision in patients with geographic atrophy, a late-stage and severe form of age-related macular degeneration (AMD).

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the worlds leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Patients with AMD often have low levels of CD59, a protein that protects the retina from damage caused by an essential part of the body's natural immune response called complement. In geographic atrophy, which affects around 5 million people globally, an overactivity of complement destroys cells in the macula, the central part of the retina.

HMR59 is designed to increase the ability of retina cells to make a soluble form of CD59, with the theory being it can help stop further damage and retain a patients vision. It has already passed a phase 1 test, with a second in patients with wet AMD currently conducting follow-up visits to evaluate long-term safety, according to a statement.

There are currently no medical treatments that can regenerate retinal cells that have atrophied, though gene therapies and stem cell therapies are the leading R&D hopes in this field.

Geographic atrophy is a devastating form of AMD that impacts the ability to accomplish everyday tasks, such as reading, driving, cooking, or even seeing faces, said James List, M.D., Ph.D., global therapeutic area head, cardiovascular and metabolism, Janssen R&D.

Our aim with this novel, single-administration gene therapy is to use our development expertise and deep heritage in vision care to help improve patient outcomes by intervening early, halting the progression to blindness, and preserving more years of sight.

RELATED: Biogen boosts gene therapy strategy with Harvard pact focused on inherited eye disease

Janssen will hope to have the success seen from gene therapy Luxturna, a drug from Novartis and Spark Therapeutics for retinal degeneration caused by mutations in the gene RPE65, after the product was approved in 2017, and helped Spark into a Roche buyout in 2019.

Other companies are also on the hunt, such as the recent tie-up between Biogen and Harvard University's Massachusetts Eye and Ear thats aimed at developing a gene therapy to help some patients with these blinding diseases.

The gene at the center of the new agreement, PRPF31, has been linked to autosomal dominant retinitis pigmentosa. Several other gene therapies are being developed to treat retinitis pigmentosa. They include Allergans RST-001, which the company picked up when it acquired RetroSense Therapeutics for $60 million in 2016.

Iveric Bio is also working on a geographic atrophy therapy, known as Zimura (avacincaptad pegol), with it posting clinically meaningful late-stage follow-up data this summer for the complement C5 inhibitor.

Read more from the original source:
Janssen buys up eye disorder gene therapy asset from Hemera Biosciences - FierceBiotech

Bayer has created a cell and gene therapy platform to support its growing pipeline of advanced therapy medicinal products. The platform is intended to enable Bayer to make its expertise and resources available to its partners while preserving their autonomy and culture.

Germanys Bayer has moved into cell and gene therapies on multiple fronts in recent years, buying up induced pluripotent stem cell specialist BlueRock Therapeutics and adeno-associated virus (AAV) gene therapy player Asklepios BioPharmaceutical while investing in a clutch of other biotechs. The deals have given Bayer a pipeline of five advanced assets and more than 15 preclinical prospects.

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the worlds leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Rather than subsume BlueRock and AskBio, Bayer opted to allow the businesses to operate as independent companies in an attempt to preserve their cultures. Yet, Bayer also wants to enable the companies to realize the benefits that can come from being part of a larger organization.

The cell and gene therapy platform is the result of that effort to get the best of both worlds. Bayer will use the platform to provide support to its cell and gene therapy businesses and orchestrate its operations in the area across the product life cycle. Specific areas of support offered by the platform span preclinical through to commercial, strategy implementation and project management.

Bayer is investing in its internal capabilities to strengthen the platform as well as looking to enter into strategic collaborations, acquire technologies and strike licensing deals. The deals entered into so far have given Bayer infrastructure as well as product candidates.

Notably, AskBio has a CDMO unit, Viralgen, specializing in AAV gene therapy production. As limited access to manufacturing capacity has been a barrier to speedy gene therapy development, buying the CDMO could help Bayer remove a constraint on the progress of its programs and become a more attractive partner for startups. Bayer thinks allowing acquired startups autonomy makes it attractive, too.

Wolfram Carius, who joined Bayer from Sanofi in 2016, is heading up the new cell and gene therapy platform. Carius said the platform is vital to accelerate innovation at its source, and to ensure its translation into tangible therapies for patients who have no time to wait in a statement.

Bayers platform is a twist on strategies being pursued by many of its peers, which have identified cell and gene therapies as growth areas and bought in assets but sought to avoid smothering the startups. Kite, for example, operates as its own business unit within Gilead Sciences, and Spark Therapeutics is an independent company within the Roche group.

More:
Bayer creates cell and gene therapy platform to support partners - FierceBiotech

Gene therapy pioneer Jim Wilson and the University of Pennsylvania are teaming up with Regeneron to help deliver its COVID-19 antibody cocktail using adeno-associated virus (AAV) tech in the hope of curbing infection via a nasal spray.

The antibody cocktail, made up of casirivimab and imdevimab, was given a speedy authorization by the FDA less than two weeks ago as a treatment for certain COVID-19 patients. But, keeping up with the fast pace of SARS-CoV-02 R&D, Regeneron is not resting on its laurels and now wants to find a quicker way of delivering its therapy while also working on it as a prophylactic.

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the worlds leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

RELATED: Regeneron, following in Lilly's footsteps, wins FDA emergency nod for COVID-19 antibody cocktail

These antibodies are currently injected into patients, but Regeneron and Penn will use Wilsons gene therapy know-how to attempt a nasal spray formulation using AAV vectors. The belief is that this could prevent infection with the virus using a technology typically used in high-tech gene therapies.

The group plans to study the safety and effectiveness of using AAV vectors to introduce the sequence of the cocktails virus-neutralizing antibodies directly to nasal epithelial cells and see whether it can help protect against the disease.

The first step is to finish preclinical trials; if successful, an IND will be sent off to the FDA for human trials.

Wilsons team said it was hopeful that introducing the therapy via single dose of AAV will be able to produce similar protection Regeneron has seen for its cocktail, but for potentially a longer duration.

Regeneron scientists specifically selected casirivimab and imdevimab to block infectivity of SARS-CoV-2, the virus that causes COVID-19, and we have been encouraged by the promising clinical data thus far, said Christos Kyratsous, Ph.D., vice president of research, infectious diseases and viral vector technologies at Regeneron.

In the quest to use cutting-edge science to help end this disruptive and often very devastating disease, we are excited to explore alternate delivery mechanisms such as AAV that may extend the potential benefits of this investigational therapy to even more people around the world.

Read this article:
Wilson, Penn ink Regeneron pact to use gene therapy tech to deliver COVID-19 antibodies - FierceBiotech

Nadofaragene firadenovec, a novel intravesical therapy for nonmuscle-invasive bladder cancer (NMIBC) that does not respond to bacillus Calmette- Gurin (BCG) therapy shows efficacy across important patient subgroups, investigators reported at SUO 2020, the virtual annual meeting of the Society of Urologic Oncology.

In the original phase 3 trial of 157 patients with high-grade BCG-unresponsive NMIBC, clinicians delivered nadofaragene firadenovec (also known as rAd-IFNa/Syn3), a non-replicating adenovirus vector-based gene therapy containing the gene interferon alfa-2b, by catheter into the bladder epithelium once every 3 months. The 3-month complete response rate was 59.6% overall and 53.4% in patients with carcinoma in situ (CIS) with or without Ta or T1 tumors. In addition, 72.9% of patients with high-grade Ta or T1 tumors and no CIS had freedom from high-grade recurrence. At 12 months, 30.5% overall, 24.3% of patients with CIS (with or without Ta or T1 tumors), and 43.8% of patients with high-grade Ta or T1 tumors (and no CIS) were free from high-grade recurrence.

For both the CIS and high-grade Ta/T1 only cohorts, there were no significant differences in response rates at 3 and 15 months between male and female patients, patients younger and older than 70 years, BCG-refractory vs BCG-relapsed disease, patients with more or less than 3 prior lines of therapy, number of prior non-BCG regimens, and patients with more or less than 3 prior courses of BCG, Vikram Narayan, MD, of Emory University in Atlanta, Georgia, reported.

Duration of response also did not differ significantly among groups, Dr Narayan reported. Only in the CIS cohort, patients who received 3 or fewer prior courses of BCG had significantly longer duration of response compared with patients who received more than 3 courses: 12.68 vs 4.96 months. A multivariable analysis confirmed that none of these baseline characteristics or prior therapy significantly influenced response rates at 3 and 15 months or duration of response.

These results demonstrate the efficacy of nadofaragene firadenovec regardless of patient characteristics or prior treatment history, Dr Narayan stated. Nadofaragene firadenovec represents a potential novel treatment option for patients with high-grade BCG-unresponsive NMIBC that advances the current treatment paradigm.

The FDA is currently reviewing a biologics license application (BLA) for nadofaragene firadenovec.

Disclosure: This clinical trial was supported by FKD Therapies in Oy, Finland. Please see the original reference for a full list of authors disclosures.

References

Narayan V, Boorjian S, Alemozaer M, et al. Subgroup analyses of the phase 3 study of intravesical nadofaragene firadenovec in patients with high-grade, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). Presented at: SUO 2020, December 3-5, 2020. Poster 23.

Boorjian SA, Alemozaffar M, Bad Konety BR, et al. Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Published online November 27, 2020. Lancet Oncol. doi:10.1016/S1470-2045(20)30540-4

Kulkarni GS. Nadofaragene firadenovec: a new gold standard for BCG-unresponsive bladder cancer? Published online November 27, 2020. Lancet Oncol. doi:10.1016/S1470-2045(20)30586-6

TechBear. FerGene announces Landmark Phase 3 study published in Lancet Oncology [news release]. FerGene; November 30, 2020.

See the rest here:
Gene Therapy for NMIBC Effective Regardless of Patient Characteristics - Renal and Urology News

Six years after Merck and Bristol Myers Squibb captured the attention of the oncology world with the first approval of their PD-1 drugs Keytruda and Opdivo, sales revenue has started to level off after a host of rivals joined the hunt for new OKs for metastatic conditions, where the FDA has proven quick to act.

But a key analyst covering biopharma believes that theres a vast, still largely untapped frontier for new approvals to come in the adjuvant setting that could once again ignite the growth of these leading cancer franchises. And once again, hes pointing to the 2 leaders in the field as the most likely players to come out ahead way, way ahead.

Unlock this story instantly and join 94,600+ biopharma pros reading Endpoints daily and it's free.

SUBSCRIBE SIGN IN

See more here:
UPDATED: Bayer continues its cell and gene therapy push, enveloping different projects under one strategic roof while hunting new deals - Endpoints...